Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $35.67 million. The enterprise value is -$962,644.

Market Cap	35.67M
Enterprise Value	-962,644

Important Dates

The next estimated earnings date is Wednesday, February 19, 2025, before market open.

Earnings Date	Feb 19, 2025
Ex-Dividend Date	n/a

Share Statistics

Opus Genetics has 31.57 million shares outstanding. The number of shares has increased by 14.60% in one year.

Current Share Class	31.57M
Shares Outstanding	31.57M
Shares Change (YoY)	+14.60%
Shares Change (QoQ)	+1.23%
Owned by Insiders (%)	4.05%
Owned by Institutions (%)	15.64%
Float	27.72M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.35
Forward PS	1.98
PB Ratio	0.86
P/TBV Ratio	1.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.63

Current Ratio	6.63
Quick Ratio	6.56
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-22.19

Financial Efficiency

Return on equity (ROE) is -64.30% and return on invested capital (ROIC) is -43.56%.

Return on Equity (ROE)	-64.30%
Return on Assets (ROA)	-38.95%
Return on Invested Capital (ROIC)	-43.56%
Return on Capital Employed (ROCE)	-85.93%
Revenue Per Employee	$598,643
Profits Per Employee	-$1.94M
Employee Count	14
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	-2,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -56.87% in the last 52 weeks. The beta is 0.24, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	-56.87%
50-Day Moving Average	1.15
200-Day Moving Average	1.40
Relative Strength Index (RSI)	47.69
Average Volume (20 Days)	144,561

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Opus Genetics had revenue of $8.38 million and -$27.19 million in losses. Loss per share was -$1.09.

Revenue	8.38M
Gross Profit	-15.39M
Operating Income	-29.47M
Pretax Income	n/a
Net Income	-27.19M
EBITDA	-29.47M
EBIT	-29.47M
Loss Per Share	-$1.09

Full Income Statement

Balance Sheet

Cash & Cash Equivalents	36.64M
Total Debt	n/a
Net Cash	36.64M
Net Cash Per Share	$1.16
Equity (Book Value)	34.30M
Book Value Per Share	1.31
Working Capital	34.30M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-13.59M
Capital Expenditures	n/a
Free Cash Flow	-13.59M
FCF Per Share	-$0.43

Full Cash Flow Statement

Margins

Gross Margin	-183.63%
Operating Margin	-351.68%
Pretax Margin	-324.47%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.60%
Shareholder Yield	-14.60%
Earnings Yield	-76.23%
FCF Yield	-38.10%

Analyst Forecast

The average price target for Opus Genetics is $8.00, which is 607.97% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.00
Price Target Difference	607.97%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	61.41%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Opus Genetics has an Altman Z-Score of 0.37 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.37
Piotroski F-Score	1